## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%); PEG 4.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($660.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. $1000 Invested In IDEXX Laboratories 20 Years Ago Would Be Worth This Much Today**
- Source: Sahm | 20251218T010932 | Bullish | Relevance: 100%
- IDEXX Laboratories (NASDAQ: IDXX) has shown significant outperformance over the past two decades, yielding an average annual return of 12.05%. An initial investment of $1000 made 20 years ago in IDXX stock would now be valued at $9,606.21. This article highlights the substantial impact of compounded returns on investment growth over time.

**2. IDEXX Laboratories, Inc. $IDXX Shares Purchased by Orion Porfolio Solutions LLC**
- Source: MarketBeat | 20251217T112021 | Bullish | Relevance: 100%
- Orion Portfolio Solutions LLC significantly increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 116.6% in Q2, bringing its total to 10,718 shares valued at approximately $5.75 million. This follows strong quarterly results where IDEXX surpassed earnings and revenue expectations and provided optimistic FY2025 guidance. Several other institutional investors also increased their stakes, with analysts maintaining a "Moderate Buy" consensus rating and an average price target of $763.50.

**3. Is Wall Street’s Optimism on IDEXX’s Diagnostics Expansion Altering the Investment Case for IDXX?**
- Source: Sahm | 20251216T050750 | Somewhat-Bullish | Relevance: 96%
- Recent upbeat coverage from Wall Street firms, including Barclays initiating an “Overweight” rating, highlights IDEXX Laboratories' growing revenue streams from veterinary and environmental diagnostics. While this reinforces IDEXX’s narrative around diagnostics innovation and global expansion, the article cautions investors to consider the company's reliance on continued instrument placements and potential risks from softer U.S. vet visit trends. Despite analyst confidence and forecast revenue growth projecting a fair value, various perspectives exist on the stock's true worth.

**4. Corient Private Wealth LLC Sells 3,030 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251216T100558 | Somewhat-Bullish | Relevance: 95%
- Corient Private Wealth LLC reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 2.5%, selling 3,030 shares, though it still holds 117,474 shares valued at $63 million. Despite this sale, institutional ownership remains high at 87.84% due to other large investors significantly increasing their holdings. IDEXX Laboratories reported a strong earnings beat and positive revenue, with a "Moderate Buy" consensus analyst rating and a price target of $763.50.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.16 signals overvaluation risk, limited margin of safety. Forward P/E 48.4x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $55.8B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.16 |
| Forward P/E | 48.4 |
| Current P/E | 54.0 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_10 - short-term weakness emerging. Long-term uptrend intact (above SMA200 at 1.22x) but short-term weakness (below SMA20). MACD histogram bearish (-5.25), momentum weakening. RSI neutral at 47. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.57% (CS: 43) | Neutral |
| RSI_14 | 46.9 | Neutral |
| MACD Histogram | -5.25 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 1.016x | Above |
| vs SMA200 | 1.221x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $697.10
- **Stop Loss:** $660.02 (5.3% risk)
- **Target:** $734.18 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 25
- **Position Value:** $17,427.50
- **Portfolio %:** 17.43%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*